An official website of the United States government
Home
Name
Orserdu
Alternate Names
Elacestrant
Abbreviations
None
Category
Hormones and hormonal mechanisms
Subcategory
Estrogen receptor degrader
SERD
NSC Number
None
Primary Site
Breast
Histology
None
Remarks
February 3, 2023 FDA approved Orserdu (elacestrant) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Coding
This drug should be coded
